Visudyne is a drug owned by Bausch And Lomb Ireland Ltd. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 11, 2016. Details of Visudyne's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5756541 | Vision through photodynamic therapy of the eye |
Mar, 2016
(8 years ago) |
Expired
|
| US5798349 | Use of green porphyrins to treat neovasculature in the eye |
Aug, 2015
(9 years ago) |
Expired
|
| US5707608 | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer |
Aug, 2015
(9 years ago) |
Expired
|
| US5770619 | Method of activating photosensitive agents |
Jan, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Visudyne is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Visudyne's family patents as well as insights into ongoing legal events on those patents.
Visudyne's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Visudyne's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 11, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Visudyne Generics:
There are no approved generic versions for Visudyne as of now.
About Visudyne
Visudyne is a drug owned by Bausch And Lomb Ireland Ltd. It is used for treating age-related macular degeneration and related conditions involving unwanted neovasculature in the eye. Visudyne uses Verteporfin as an active ingredient. Visudyne was launched by Bausch Lomb Ireland in 2000.
Approval Date:
Visudyne was approved by FDA for market use on 12 April, 2000.
Active Ingredient:
Visudyne uses Verteporfin as the active ingredient. Check out other Drugs and Companies using Verteporfin ingredient
Treatment:
Visudyne is used for treating age-related macular degeneration and related conditions involving unwanted neovasculature in the eye.
Dosage:
Visudyne is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 15MG/VIAL | INJECTABLE | Prescription | INJECTION |